Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Common Equity (2016 - 2025)

Historic Common Equity for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $372.8 million.

  • Myriad Genetics' Common Equity fell 4905.02% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.8 million, marking a year-over-year decrease of 4905.02%. This contributed to the annual value of $701.1 million for FY2024, which is 1048.26% down from last year.
  • As of Q3 2025, Myriad Genetics' Common Equity stood at $372.8 million, which was down 4905.02% from $388.1 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Common Equity registered a high of $968.6 million during Q3 2021, and its lowest value of $372.8 million during Q3 2025.
  • Over the past 5 years, Myriad Genetics' median Common Equity value was $783.2 million (recorded in 2023), while the average stood at $781.6 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 985.24% in 2021, then crashed by 4905.02% in 2025.
  • Myriad Genetics' Common Equity (Quarter) stood at $967.8 million in 2021, then dropped by 8.47% to $885.8 million in 2022, then decreased by 11.58% to $783.2 million in 2023, then dropped by 10.48% to $701.1 million in 2024, then plummeted by 46.83% to $372.8 million in 2025.
  • Its Common Equity was $372.8 million in Q3 2025, compared to $388.1 million in Q2 2025 and $704.9 million in Q1 2025.